| Company Name: |
Shanghai Hongye Biotechnology Co. Ltd
|
| Tel: |
400-9205774 |
| Email: |
sales@glpbio.cn |
| Products Intro: |
Product Name:Regorafenib-13C-d3
CAS:2126178-55-8
Purity:>98% Package:1mg;10mg;50mg;100mg;
|
| Company Name: |
QUALITY CONTROL SOLUTIONS LTD.
|
| Tel: |
13670046396 |
| Email: |
ORDERS@QCSRM.COM |
| Products Intro: |
Product Name:Regorafenib-13C-d3
Purity:95% HPLC Package:10MG;25MG;50MG;100MG
|
| Company Name: |
Nanjing Tengyi Biotechnology Co., Ltd
|
| Tel: |
025-58851786 17714337195 |
| Email: |
sales@tybiochem.com |
| Products Intro: |
Product Name:4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-(methyl-13C-d3)-2-pyridinecarboxamide
CAS:2126178-55-8
Purity:95+% Package:1g;5g
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:Regorafenib-13C-d3
CAS:2126178-55-8
Purity:>95% Package:500μg;1mg
|
|
| | Regorafenib-13C-d3 Basic information |
| Product Name: | Regorafenib-13C-d3 | | Synonyms: | Regorafenib-13C-d3;4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-(methyl-13C-d3)-2-pyridinecarboxamide | | CAS: | 2126178-55-8 | | MF: | C21H12ClD3F4N4O3 | | MW: | 486.842898134 | | EINECS: | | | Product Categories: | | | Mol File: | 2126178-55-8.mol |  |
| | Regorafenib-13C-d3 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 14 mg/ml | | form | A solid |
| | Regorafenib-13C-d3 Usage And Synthesis |
| Description | Regorafenib-13C-d3 is intended for use as an internal standard for the quantification of regorafenib by GC- or LC-MS. Regorafenib is an orally bioavailable multi-kinase inhibitor with anticancer activity.1 It inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ with IC50 values of 1.5, 2.5, 4.2, 7, 13, and 22 nM, respectively. Regorafenib also inhibits B-RAF, VEGFR3, FGFR, and Tie2 (IC50s = 28, 46, 202, and 311 nM, respectively) as well as other kinases.1,2,3 In vivo, regorafenib (10 mg/kg) reduces tumor size in the MDA-MB-231 breast and 786-O renal cancer mouse xenograft models.1 It also reduces tumor microvessel area and inhibits tumor growth in a panel of mouse xenograft models. Formulations containing regorafenib have been used in the treatment of advanced gastrointestinal stromal tumors and metastatic colorectal cancer. | | References | 1. Wilhelm, S.M., Dumas, J., Adnane, L., et al. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Int. J. Cancer 129(1),245-255(2011).
2. Uitdehaag, J.C.M., de Roos, J.A.D.M., van Doornmalen, A.M., et al. Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use PLoS One 9(3),1-13(2014).
3. Ravi, S., and Singal, A.K. Regorafenib: An evidence-based review of its potential in patients with advanced liver cancer Core Evid. 9,81-87(2014). |
| | Regorafenib-13C-d3 Preparation Products And Raw materials |
|